SCHEMBL23328272

SCHEMBL23328272

C=CC(=O)N1CCC(CCCC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TEAD1 P28347 4/20 0.49
TEAD3 Q99594 2/20 0.49
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
ITGB3 P05106 2/20 0.38
ITGA2B P08514 2/20 0.38
GNAI3 P08754 2/20 0.36
GNAO1 P09471 2/20 0.36
GNAI1 P63096 2/20 0.36
JAK3 P52333 3/20 0.36
JAK2 O60674 2/20 0.36
JAK1 P23458 2/20 0.36
BTK Q06187 2/20 0.35
FGFR1 P11362 2/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35
FAAH O00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16030874 0.87 TEAD1 (0.56) TEAD1TEAD3ITGB3ITGA2BGNAI3
SCHEMBL18904847 0.83 THRA (0.54) TEAD1TEAD3THRATHRBJAK3
SCHEMBL18328751 0.80 TEAD1 (0.54) TEAD1TEAD3GNAI3GNAO1GNAI1
SCHEMBL18616043 0.79 TEAD1 (0.53) TEAD1TEAD3ITGB3ITGA2BGNAI3
SCHEMBL25904097 0.79 ITGB3 (0.40) ITGB3ITGA2BGNAI3GNAO1GNAI1
SCHEMBL23328296 0.79 TEAD1 (0.36) TEAD1TEAD3THRATHRBJAK3
SCHEMBL23328572 0.79 FGFR1 (0.38) TEAD1TEAD3JAK3BTKFGFR1
SCHEMBL18333367 0.78 TEAD1 (0.55) TEAD1TEAD3JAK3JAK2JAK1
SCHEMBL15474338 0.78 THRA (0.47) TEAD1TEAD3THRATHRBJAK3
SCHEMBL23328270 0.78 TEAD3 (0.47) TEAD3FGFR1FGFR2FGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 TEAD1 1181/4885TEAD3 1649/4885THRA 3633/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 TEAD1 1176/4885TEAD3 1580/4885THRA 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.